Idecabtagene vicleucel – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 09 Mar 2023 11:31:45 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Idecabtagene vicleucel – VJRegenMed https://mirror.vjregenmed.com 32 32 KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma https://mirror.vjregenmed.com/video/oaqi76v70nw-karmma-3-results-ide-cel-vs-standard-regimens-in-triple-class-exposed-multiple-myeloma/ Thu, 09 Mar 2023 11:31:45 +0000 https://mirror.vjregenmed.com/video/oaqi76v70nw-karmma-3-results-ide-cel-vs-standard-regimens-in-triple-class-exposed-multiple-myeloma/ In this video, Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, gives an overview of the results of the KarMMa-3 study (NCT03651128), a Phase III trial comparing idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple class–exposed relapsed/refractory (R/R) multiple myeloma. The study reported a significant benefit for ide-cel in terms of complete remission (CR) rate and progression-free survival (PFS) across all risk categories. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]>
Targeting neoantigens in multiple myeloma with CAR T-cell https://mirror.vjregenmed.com/video/ubjgupfy51i-targeting-neoantigens-in-multiple-myeloma-with-car-t-cell/ Tue, 12 Apr 2022 11:18:09 +0000 http://13.40.107.223/video/ubjgupfy51i-targeting-neoantigens-in-multiple-myeloma-with-car-t-cell/ Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies such as ciltacabtagene autoleucel and idecabtagene vicleucel have made a positive impact on the treatment landscape of multiple myeloma. However, tumor heterogeneity, antigen escape and an immunosuppressive tumor microenvironment are barriers CAR T-cell therapies currently face. Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, describes research on neoantigens and its benefits. As neoantigens are only found in the tumor, off-target effects such as B-cell aplasia and cytokine release syndrome (CRS) are reduced. Utilizing alternative targets such as SLAMF7 and CD38, as well as bispecific CAR T-cells represent novel strategies to optimize immunotherapies for multiple myeloma. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

]]>
The European cell & gene therapy landscape https://mirror.vjregenmed.com/video/uhgs1bta_zs-the-european-cell-gene-therapy-landscape/ Sat, 10 Apr 2021 10:58:01 +0000 http://13.40.107.223/video/uhgs1bta_zs-the-european-cell-gene-therapy-landscape/ Paige Bischoff, Senior VP of Global Public Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., provides an overview of the cell and gene therapy sector in Europe. In 2021, there are currently five approved gene therapies and six cell therapies on market in Europe but it is predicted that by 2025, the European Medicines Agency (EMA) will approve 10-20 new cell and gene therapies each year. It is therefore important that current challenges surrounding policy, regulation and reimbursement are addressed in the near future. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]>
CAR-T in myeloma: key players in the therapeutic landscape https://mirror.vjregenmed.com/video/vnvjiwnrdac-car-t-in-myeloma-key-players-in-the-therapeutic-landscape/ Fri, 26 Feb 2021 14:08:25 +0000 http://13.40.107.223/video/vnvjiwnrdac-car-t-in-myeloma-key-players-in-the-therapeutic-landscape/ Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses CAR T-cell therapy for multiple myeloma. Although the multiple myeloma treatment landscape is rapidly evolving and the development of new therapies has greatly improved outcomes, patients with triple or penta-refractory disease still have limited treatment options. Recently, clinical trials investigating CAR T-cells for multiple myeloma have demonstrated promising clinical activity, showing unprecedented response rates in these heavily pre-treated patient population. Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are among several BCMA CAR T-cell products in later stages of clinical trials, and it is anticipated that they will be approved in 2021. Prof. Mohty believes that the whole treatment paradigm will see some significant changes in the next five years as CAR T-cells move into earlier lines of therapy. Additionally, Prof. Mohty highlights other immunotherapy strategies, such as BiTEs, as well as novel targets. This interview took place during the 3rd European CAR T-cell Meeting.

]]>
Clinical advances with CAR-Ts and bispecifics in R/R myeloma https://mirror.vjregenmed.com/video/nlbyumq8hty-clinical-advances-with-car-ts-and-bispecifics-in-rr-myeloma/ Fri, 26 Feb 2021 14:08:23 +0000 http://13.40.107.223/video/nlbyumq8hty-clinical-advances-with-car-ts-and-bispecifics-in-rr-myeloma/ Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the recent clinical advances with CAR T-cells and bispecifics in relapsed/refractory (R/R) multiple myeloma. Over the past decade, new treatments have transformed survival outcomes of myeloma. However, patients with myeloma refractory to the therapies that currently comprise the hematologic standard of care, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies, have limited treatment options. It is expected that additional agents will be available for triple-refractory disease soon. Dr Mateos highlights idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), both BCMA-targeting CAR T-cells. Various bispecific monoclonal antibodies targeting BCMA are currently in development, with promising results. This interview took place during the 3rd European CAR T-cell Meeting.

]]>